Your search for desvenlafaxine returned 20 results

Your search for desvenlafaxine returned 20 results

Sort Results:

Relevant Recent
Drug Monograph

Desvenlafaxine

Desvenlafaxine 50mg, 100mg; ext-rel tabs.
Drug Monograph

PRISTIQ

Desvenlafaxine (as succinate) 25mg, 50mg, 100mg; ext-rel tabs.
News

Khedezla Now Available for Depression

Par Pharmaceutical announced the launch of Khedezla (desvenlafaxine) ER tablets for the treatment of major depressive disorder.
Drugs in the Pipeline

Top Line Results for Pristiq in Pediatric MDD Announced

Pfizer announced top line results from a Phase 3 study evaluating Pristiq (desvenlafaxine succinate sustained-release formulation) in pediatric patients ages 7-17 with Major Depressive Disorder (MDD).
Drug News

Desvenlafaxine for Painful Diabetic Peripheral Neuropathy?

Purpose: To assess the safety and efficacy of the serotonin–norepinephrine reuptake inhibitor desvenlafaxine in adults with painful diabetic peripheral neuropathy (DPN). Patients and methods: This was a 13-week, randomized, double-blind, placebo-controlled, fixed-dose study of desvenlafaxine in adults with painful DPN.
Slideshow

New Drug Product: KHEDEZLA

This slideshow reviews drug information for KHEDEZLA (desvenlafaxine). Click here for the complete KHEDEZLA new product monograph.
News

Pristiq approved for MDD

Wyeth has received FDA approval for Pristiq (desvenlafaxine) for the treatment of adult patients with major depressive disorder (MDD).
News

Neurocognitive and Work Functioning Improved with Desvenlafaxine

A study published in the Journal of Affective Disorders concluded that there were no significant associations between changes in neurocognitive and work functioning measures in employed patients with major depressive disorder (MDD).